Sign in
Not yet taking people in United StatesNo phase

Testing the BlinkER device for people with facial nerve palsy

Tests the BlinkER device in adults with facial nerve palsy.

Key facts

Who runs it
Neurotrigger Ltd
Where
Deerfield Beach, United StatesSee the site
Trial code
Registry title
Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy
Status
Not yet recruiting
People taking part
80 people, planned
Started
1 Oct 2025
Expected to end
30 Nov 2026
Type of study
Interventional
Treatments tested
  • BlinkER device.
Record updated
10 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with facial palsy on one side of the face who cannot fully close the eye when blinking. They will test the BlinkER System device for up to 3 months.

Age
22 years or older (up to 120 years).
Sex
All sexes can join.
Disease stage
Facial palsy on one side only, caused by Bell's palsy, Ramsay Hunt syndrome, removal of a tumor (cancer or not), Lyme disease, stroke (bleeding or blocked blood flow) or injury. The eye must not close well during blinking (mean blink score ≤2.0 on the Mäkelä scale).
Earlier treatment
People who already had a procedure that closes the eyelids (such as facial reanimation or complete tarsorrhaphy surgery) cannot join. People with an eyelid weight implanted in the study eyelid cannot join.
Biomarker or test result
In a test with the BlinkER System, the device must make blinks that cover the pupil (mean grade ≥ 3.0 on the Mäkelä scale). Participants must complete BlinkER System training and certification. Participants must speak English, Spanish, Hebrew or Arabic.

Main reasons for not taking part

  • Facial paralysis on both sides
  • Epilepsy, suspected or diagnosed
  • Pacemaker, implanted defibrillator or other implanted electronic device
  • Eye infection, severe eye surface inflammation, or problems of the cornea or iris
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • 22 years of age or older
  • Unilateral facial palsy due to any of the following: Bell's palsy, Ramsay Hunt syndrome, malignant or benign tumor resection, Lyme disease, cerebrovascular accident (hemorrhagic or ischemic), or trauma
  • A deficit in eye closure during blinking, defined as a mean blink score ≤2.0 in the study eye on the scale by Mäkelä, et al, as graded by the investigator
  • Willing and able to comply with the study procedures and follow-up
  • Willing and able to provide informed consent
  • English, Spanish, or Hebrew, Arabic -speaking
  • In a trial with the BlinkER System, the device produces blinks sufficient to cover the pupil in the study eye, defined as a mean grade ≥ 3.0 on the Mäkelä scale, as graded by the investigator
  • Participant successfully completes BlinkER System training and certification

Who cannot take part

  • History of prior intervention that is providing closure of the eyelids (e.g., facial reanimation, complete tarsorrhaphy surgery, etc.)
  • Participation in another ophthalmic clinical trial within one year prior to enrollment. Participant must also be willing to refrain from another ophthalmic study for the duration of the study
  • Bilateral facial paralysis (for example Parkinson's Disease)
  • History of diabetic neuropathy, unstable cardiovascular disease, neurologic disease causing severe cognitive or motor impairment, severe immunological deficiency, or malignant diseases that are not in remission
  • Signs of corneal infection, severe ocular surface inflammation, or significant periorbital skin inflammation/infection
  • Suspected or diagnosed epilepsy
  • Cardiac demand pacemaker, implanted defibrillator or other implanted electronic device
  • Known allergy to any of the patient-contacting materials of the BlinkeER electrode (i.e. polyethylene (PET) film tape or hydrogel)
  • Co-existing condition, either ocular or non-ocular that, in the judgement of the investigator could affect the safety or effectiveness of treatment or the compliance of the participant to the protocol
  • Has an implanted eyelid weight in the study eyelid
  • Cancerous lesions in the area where the BlinkER system electrodes will be applied
  • Cornea or iris abnormalities that preclude visualization of the pupil
  • Cranial nerve V palsy or neurotrophic keratitis
  • Synkinesis that results in eyelid closure
  • Participants who are pregnant or nursing

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 22 and 120 years old?

Where in United States

  • Rand Eye InstituteDeerfield Beach, United StatesContact: Alison Rand, MDNot yet recruiting

About the trial

What the trial wants to find out

Prospective, single-arm, multicenter, single-masked, pivotal study to Evaluate the Safety and Effectiveness of the Blinker system in Participants with Facial Nerve Palsy.

The group in the trial

  • BlinkER system treatmentTreatment being tested

    A prospective single-arm multicenter pivotal study designed to evaluate the safety and effectiveness of the BlinkER System in achieving eyelid closure in participants with facial nerve palsy. Participants will receive the NeuroTrigger Basic System and use it for up to 3 months.

    Treatment: BlinkER device.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Single-Arm, Multicenter Study to Evaluate the Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy
Plain-language title
Testing the BlinkER device for people with facial nerve palsyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06542289, who can take part
Record updated
10 June 2025